Form 4: Arbutus Biopharma Director Frank Torti Granted Stock Options

Director Frank Torti of Arbutus Biopharma Corp. received stock options for 67,000 common shares on May 23, 2024, fully vested and exercisable immediately.

Summary

• On May 23, 2024, Frank Torti, a director of Arbutus Biopharma Corporation, was granted stock options to purchase 67,000 common shares.
• The exercise price of these options is $3.28 per share, reflecting the closing price of Arbutus Biopharma's common shares on the Nasdaq Stock Market on the grant date.
• The options are fully vested and exercisable as of the grant date and expire on May 23, 2034.
• This transaction was reported on a Form 4 filing with the Securities and Exchange Commission.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The granting of stock options to a director is a routine corporate action that aligns interests with shareholders, suggesting confidence in the company's future performance.

Positives

• The immediate vesting of the options suggests confidence in the director's continued contributions to the company.
• The grant aligns the director's interests with those of the shareholders, as the options' value increases with the company's stock price.

Future Outlook

The document does not contain specific forward-looking statements, but the option grant suggests an expectation of future value creation.

Industry Context

Stock option grants are a common practice in the biopharmaceutical industry to incentivize and retain key personnel, aligning their interests with the long-term success of the company.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotechnology industry.
• Companies like Gilead Sciences and Vertex Pharmaceuticals also use stock options to incentivize their directors and officers.
• The size of the grant (67,000 shares) would need to be compared to similar grants at peer companies to assess its relative magnitude.

Stakeholder Impact

• Shareholders may view the option grant positively as it aligns the director's interests with the company's performance.
• Employees may see it as a sign of confidence in the company's future.

Key Dates